Kintor Pharmaceutical Limited
KNTPF
$0.3643
$0.034910.60%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 203.36% | 204.21% | -- | -- | -- |
| Gross Profit | -81.73% | -81.57% | -- | -- | -- |
| SG&A Expenses | 49.54% | 50.73% | -42.31% | -43.18% | -53.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -3,431.22% | -3,456.51% | 68.56% | 69.02% | 106.43% |
| Total Operating Expenses | -90.10% | -90.02% | -68.13% | -68.62% | 82.40% |
| Operating Income | 90.72% | 90.64% | 68.13% | 68.62% | -82.40% |
| Income Before Tax | 90.18% | 90.10% | 67.47% | 67.96% | -93.78% |
| Income Tax Expenses | 100.00% | 100.00% | 103.31% | 103.50% | -789.17% |
| Earnings from Continuing Operations | 90.09% | 90.01% | 67.39% | 67.88% | -91.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 90.09% | 90.01% | 67.39% | 67.88% | -91.60% |
| EBIT | 90.72% | 90.64% | 68.13% | 68.62% | -82.40% |
| EBITDA | 91.51% | 91.44% | 69.92% | 70.38% | -83.81% |
| EPS Basic | 90.13% | 90.03% | 67.42% | 67.96% | -72.73% |
| Normalized Basic EPS | 90.44% | 90.41% | 67.57% | 68.28% | -64.85% |
| EPS Diluted | 90.13% | 90.03% | 67.42% | 67.96% | -72.73% |
| Normalized Diluted EPS | 90.44% | 90.41% | 67.57% | 68.28% | -64.85% |
| Average Basic Shares Outstanding | 0.31% | 0.31% | 0.46% | 0.46% | 10.91% |
| Average Diluted Shares Outstanding | 0.31% | 0.31% | 0.46% | 0.46% | 10.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |